APA (7th ed.) Citation

K, S., A, B., M, K., A, N., M, I., J, O., . . . V, Š. D. (2026). Cosegregation analysis following an excellent response to olaparib in a pancreatic cancer patient carrier of BRCA2: C.7892 T > C variant enables its reclassification from VUS to pathogenic. BJC reports, 4(1), 5. https://doi.org/10.1038/s44276-026-00206-0

Chicago Style (17th ed.) Citation

K, Strojnik, et al. "Cosegregation Analysis Following an Excellent Response to Olaparib in a Pancreatic Cancer Patient Carrier of BRCA2: C.7892 T > C Variant Enables Its Reclassification from VUS to Pathogenic." BJC Reports 4, no. 1 (2026): 5. https://doi.org/10.1038/s44276-026-00206-0.

MLA (9th ed.) Citation

K, Strojnik, et al. "Cosegregation Analysis Following an Excellent Response to Olaparib in a Pancreatic Cancer Patient Carrier of BRCA2: C.7892 T > C Variant Enables Its Reclassification from VUS to Pathogenic." BJC Reports, vol. 4, no. 1, 2026, p. 5, https://doi.org/10.1038/s44276-026-00206-0.